Avastin use restricted

Bevacizumab blocks the action of VEGF, thus inhibiting angiogenesis
Bevacizumab blocks the action of VEGF, thus inhibiting angiogenesis

Use of bevacizumab (Avastin) in patients with metastatic breast cancer has been restricted to combination therapy with the taxane, paclitaxel.

The antibody was previously also licensed for use with another taxane, docetaxel. However, new data submitted to the Committee for Medicinal Products for Human Use showed that the combination of bevacizumab with docetaxel has a smaller effect on progression-free survival than previously thought, and may even reduce overall survival. Accordingly, use of this combination is no longer recommended.

The Committee concluded that the risk-benefit balance for combination use of bevacizumab with paclitaxel remains positive.

The other indications of Avastin, including non-small cell lung cancer, colorectal cancer and renal cell carcinoma, are unaffected by the change.

View Avastin drug record

Further information: Roche

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases